KR20240153351A - 디펩티딜 펩티다제 억제제 화합물의 염 및 결정형 - Google Patents

디펩티딜 펩티다제 억제제 화합물의 염 및 결정형 Download PDF

Info

Publication number
KR20240153351A
KR20240153351A KR1020247031067A KR20247031067A KR20240153351A KR 20240153351 A KR20240153351 A KR 20240153351A KR 1020247031067 A KR1020247031067 A KR 1020247031067A KR 20247031067 A KR20247031067 A KR 20247031067A KR 20240153351 A KR20240153351 A KR 20240153351A
Authority
KR
South Korea
Prior art keywords
crystalline form
formula
compound
present
provides
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020247031067A
Other languages
English (en)
Korean (ko)
Inventor
지앙 판
잉 두
젱 공
펭페이 주
Original Assignee
하이스코 파마수티컬즈 피티이. 엘티디.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 하이스코 파마수티컬즈 피티이. 엘티디. filed Critical 하이스코 파마수티컬즈 피티이. 엘티디.
Publication of KR20240153351A publication Critical patent/KR20240153351A/ko
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D267/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D267/02—Seven-membered rings
    • C07D267/08—Seven-membered rings having the hetero atoms in positions 1 and 4
    • C07D267/10—Seven-membered rings having the hetero atoms in positions 1 and 4 not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cooling Or The Like Of Semiconductors Or Solid State Devices (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020247031067A 2022-02-22 2023-02-21 디펩티딜 펩티다제 억제제 화합물의 염 및 결정형 Pending KR20240153351A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN202210160862 2022-02-22
CN202210160862.5 2022-02-22
PCT/CN2023/077409 WO2023160542A1 (zh) 2022-02-22 2023-02-21 二肽基肽酶抑制剂化合物的盐及晶型

Publications (1)

Publication Number Publication Date
KR20240153351A true KR20240153351A (ko) 2024-10-22

Family

ID=87764787

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020247031067A Pending KR20240153351A (ko) 2022-02-22 2023-02-21 디펩티딜 펩티다제 억제제 화합물의 염 및 결정형

Country Status (13)

Country Link
US (1) US20250188067A1 (cg-RX-API-DMAC10.html)
EP (1) EP4484414A4 (cg-RX-API-DMAC10.html)
JP (1) JP2025508792A (cg-RX-API-DMAC10.html)
KR (1) KR20240153351A (cg-RX-API-DMAC10.html)
CN (1) CN118660873A (cg-RX-API-DMAC10.html)
AU (1) AU2023225835A1 (cg-RX-API-DMAC10.html)
CA (1) CA3243683A1 (cg-RX-API-DMAC10.html)
CL (1) CL2024002490A1 (cg-RX-API-DMAC10.html)
IL (1) IL314852A (cg-RX-API-DMAC10.html)
MX (1) MX2024010180A (cg-RX-API-DMAC10.html)
TW (1) TW202342466A (cg-RX-API-DMAC10.html)
WO (1) WO2023160542A1 (cg-RX-API-DMAC10.html)
ZA (1) ZA202407225B (cg-RX-API-DMAC10.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2025506307A (ja) * 2022-02-22 2025-03-07 ハイスコ ファーマスーティカル プライベート リミテッド 含窒素複素環化合物の調製方法
JP2026503035A (ja) 2023-01-06 2026-01-27 インスメッド インコーポレイテッド 新規な可逆性dpp1阻害剤及びその用途
WO2025162472A1 (en) 2024-01-31 2025-08-07 Insmed Incorporated Linear dipeptidyl peptidase 1 inhibitors and uses thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7902181B2 (en) * 2007-12-12 2011-03-08 Astrazeneca Ab Compounds 010
NO2699580T3 (cg-RX-API-DMAC10.html) * 2014-01-24 2018-02-24
PL4129989T3 (pl) * 2020-08-26 2025-02-24 Haisco Pharmaceuticals Pte. Ltd. Pochodna nitrilu działająca jako inhibitor dipeptydylopeptydazy 1 i jej zastosowanie
CN114106005B (zh) * 2020-08-26 2025-08-01 西藏海思科制药有限公司 一种作为二肽基肽酶1抑制剂的腈衍生物及其用途
CN114591315A (zh) * 2020-12-04 2022-06-07 瑞石生物医药有限公司 一种组织蛋白酶c小分子抑制剂
WO2022166721A1 (zh) * 2021-02-05 2022-08-11 南京明德新药研发有限公司 含1,4-氧杂氮杂环庚烷的并环类衍生物

Also Published As

Publication number Publication date
EP4484414A1 (en) 2025-01-01
TW202342466A (zh) 2023-11-01
IL314852A (en) 2024-10-01
AU2023225835A1 (en) 2024-10-03
CL2024002490A1 (es) 2024-12-13
MX2024010180A (es) 2024-08-27
ZA202407225B (en) 2025-12-17
CA3243683A1 (en) 2025-01-22
JP2025508792A (ja) 2025-04-10
US20250188067A1 (en) 2025-06-12
WO2023160542A1 (zh) 2023-08-31
EP4484414A4 (en) 2026-01-28
CN118660873A (zh) 2024-09-17

Similar Documents

Publication Publication Date Title
EP4484414A1 (en) Salt and crystal form of dipeptidyl peptidase inhibitor compound
EP4484424A1 (en) Dipeptidyl peptidase 1 inhibitor polymorph, preparation method and use therefor
EP1853232B1 (en) Stable crystalline form of bifeprunox mesylate, dosage forms thereof adn methods for using them
KR20250023398A (ko) 벤조[c]크로만 화합물의 약학적으로 허용되는 염, 상기 약학적으로 허용되는 염의 다형체 형태 및 용도
KR101557832B1 (ko) (r)-3-플루오로페닐-3,4,5-트리플루오로벤질카르밤산 1-아자비시클로 [2.2.2]옥트-3-일 에스테르의 안정한 결정성 염
EP4667465A1 (en) Salt of benzo-nitrogen heteroaromatic ring derivative, crystalline form, and pharmaceutical use thereof
JP4015954B2 (ja) トシル酸スプラタスト結晶
CN116041324B (zh) 一种氘代吡唑二氯苯甲酰胺类化合物、药物组合物和用途
EP3466945A1 (en) Pharmaceutically acceptable salt as renal outer medullary potassium channel inhibitor
EA053095B1 (ru) Соль и кристаллическая форма соединения, являющегося ингибитором дипептидилпептидазы
US7824710B2 (en) Crystalline and stable form of andolast
EP4596541A1 (en) Novel crystalline form of enavogliflozin, and preparation method therefor
US20190062307A1 (en) Deuterium-substituted quinoline derivatives
EP3517529B1 (en) Salt of quinazoline derivative, preparation method therefor and application thereof
CA3268822A1 (en) Novel crystalline form of enavogliflozin, and preparation method therefor
EP4653441A1 (en) Salt of antidepressant compound, and preparation method therefor, pharmaceutical composition containing same and use thereof
EA051477B1 (ru) Полиморф ингибитора дипептидилпептидазы 1, способ его получения и применение
CN116396305A (zh) 一种稠环衍生物的晶型、其制备方法及其应用
HK1109629A (en) A new crystalline and stable form of andolast
HK1175780B (en) Crystalline cdc7 inhibitor salts
HK1175780A1 (en) Crystalline cdc7 inhibitor salts

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20240913

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application